Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience’s Xafty by UCSD
SAN DIEGO, Sept. 17, 2024 /PRNewswire/ — Hyundai Bioscience USA announced that it has signed an MOU with the University of California San Diego (UCSD) to conduct an investigator-initiated trial to evaluate the efficacy of Xafty®, a niclosamide-based antiviral developed by its Korean…
XCharge, Asia Green Fund’s Portfolio, Successfully Listed on Nasdaq
BEIJING, Sept. 14, 2024 /PRNewswire/ — XCHG Limited (XCHARGE) (NASDAQ: XCH) announced the pricing of its initial public offering. XCharge, founded in 2015, is a global leader in integrated EV charging solutions, focusing on Innovative New Energy Technologies and Sustainable Development ….
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gogoro Inc. – GGR
NEW YORK, Sept. 17, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Gogoro Inc. (“Gogoro” or the “Company”) (NASDAQ: GGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation…
Viatris Announces Early Tender Results and Increase of Pending Maximum Tender Offer
PITTSBURGH, Sept. 17, 2024 /PRNewswire/ — Viatris Inc. (NASDAQ: VTRS, “Viatris” or the “Company”) announced today the early tender results of the previously announced cash tender offer (the “Maximum Tender Offer”) of its subsidiary Utah Acquisition Sub Inc. (“UAS”) and that UAS has…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adobe Inc. – ADBE
NEW YORK, Sept. 17, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Adobe Inc. (“Adobe” or the “Company”) (NASDAQ: ADBE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation…
WILDBRAIN REPORTS FULL YEAR AND Q4 2024 RESULTS
Fiscal 2024 Highlights Revenue was $461.8 million, compared to $532.9 million in FY2023. Net loss was $106.0 million, compared with net loss of $45.6 million in FY2023. Adjusted EBITDA1 was $87.6 million, compared to $97.9 million in FY2023. Cash provided by operating activities was $73.6…
Clorox Declares Regular Quarterly Dividend of $1.22 Per Share
OAKLAND, Calif., Sept. 17, 2024 /PRNewswire/ — The Clorox Company (NYSE: CLX) announced today that its board of directors has declared a quarterly dividend of $1.22 per share on the company’s common stock. The dividend is payable November 7, 2024, to shareholders of record as of the…
UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES PRICING OF SENIOR SECURED NOTES
KING OF PRUSSIA, Pa., Sept. 17, 2024 /PRNewswire/ — Universal Health Services, Inc. (NYSE: UHS) today announced the pricing of its previously announced public offering of senior secured notes. The Company priced the offering of $500 million aggregate principal amount of its 4.625% senior…
Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors at the 2024 ESMO Congress
SAN FRANCISCO and SUZHOU, China, Sept. 17, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and…
Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress
SAN FRANCISCO and SUZHOU, China, Sept. 17, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and…